|
发表于 2014-5-15 13:56:22
|
显示全部楼层
来自: 中国湖南衡阳
(转当下大哥的帖子)已知的肺腺癌致癌驱动(根源)基因 和 靶向药,可以尝试:
EGFR - 特罗凯, 易瑞莎, 2992阿法替尼, WZ4002,凡德它尼
ALK - Crizotinib克药, LDK378, AP26113, CH5424802
BRAF - share targeted therapy with melanoma drug, Vemurafenib
HER2 - share targeted therapy with breast cancer, herceptin,2992,PF299804
KRAS - Selumetinib 司美替尼, 代号AZD6244.
MET - Crizotinib克药, and prostate cancer drug cabozantinib XL-184
PIK3CA - BLM120(有YL药了)
RET - share targeted therapy with GIST and kidney cancer drug, Sunitinib(索坦); leukemia drug ponatinib; thyroid cancer drug Vandetanib(凡德); and prostate cancer drug Cabozantinib (XL184)
ROS - Crizotinib克药, AP26113
T790M - WZ4002,CO-1686
非基因驱动的VEGF抗血管生成靶向药:
VEGF:阿西替尼,T药,索拉,索坦,凡德(后三个药是含V的多靶点)。
试药顺序,有点我要特别提出:考虑到EGFR的特/易,及ALK的克药是靶向中的大款药;在试药时先试EGFR靶点的特/易,若无效,紧接马上试ALK的克药;若特/易有效,则可以不用试ALK的药,接着2992,VEGF类的。。。
|
|